Last reviewed · How we verify
Pyrazinamide Oral Product
Pyrazinamide is converted to pyrazinoic acid in mycobacteria, which disrupts bacterial cell wall synthesis and energy metabolism, leading to mycobacterial cell death.
Pyrazinamide is converted to pyrazinoic acid in mycobacteria, which disrupts bacterial cell wall synthesis and energy metabolism, leading to mycobacterial cell death. Used for Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy.
At a glance
| Generic name | Pyrazinamide Oral Product |
|---|---|
| Sponsor | Wits Health Consortium (Pty) Ltd |
| Drug class | Antituberculous agent |
| Target | Pantothenate synthetase (PanC); pyrazinamidase activation required |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Pyrazinamide is a prodrug that requires activation by the mycobacterial enzyme pyrazinamidase to form pyrazinoic acid. The active metabolite inhibits the enzyme pantothenate synthetase and disrupts mycobacterial fatty acid synthesis, which is essential for cell wall integrity. This mechanism is particularly effective against intracellular and dormant Mycobacterium tuberculosis.
Approved indications
- Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy
Common side effects
- Hyperuricemia
- Gout
- Hepatotoxicity
- Nausea
- Vomiting
- Arthralgia
Key clinical trials
- Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis (PHASE2)
- Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- PanACEA - STEP2C -01 (PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (PHASE3)
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2, PHASE3)
- Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis (PHASE2)
- Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyrazinamide Oral Product CI brief — competitive landscape report
- Pyrazinamide Oral Product updates RSS · CI watch RSS
- Wits Health Consortium (Pty) Ltd portfolio CI